F-Flortaucipir Tau Positron Emission Tomography Distinguishes Established Progressive Supranuclear Palsy from Controls and Parkinson Disease: A Multicenter Study
暂无分享,去创建一个
Daniel R. Schonhaut | W. Jagust | B. Dickerson | M. Grossman | J. Kramer | W. Seeley | A. Siderowf | A. Boxer | G. Rabinovici | I. Litvan | C. McMillan | S. Gomperts | E. Roberson | M. Devous | S. Baker | Richard M Tsai | P. Pressman | Joseph R. Winer | S. Spina | I. Nasrallah | D. S. Russell | Bruce L Miller | L. Grinberg | PsyD | Keith A. Johnson | Bruce L. Miller | Richard M. Tsai | J. Winer | D. Russell | B. Miller | M. Grossman | C. Mcmillan | Ilya Nasrallah
[1] Alan A. Wilson,et al. Positron emission tomography imaging of tau pathology in progressive supranuclear palsy , 2017, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[2] Murray Grossman,et al. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria , 2017, Movement disorders : official journal of the Movement Disorder Society.
[3] Rupert Lanzenberger,et al. Modeling Strategies for Quantification of In Vivo 18F-AV-1451 Binding in Patients with Tau Pathology , 2017, The Journal of Nuclear Medicine.
[4] S. Gauthier,et al. Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain , 2017, Alzheimer's Research & Therapy.
[5] Suzanne L Baker,et al. Reference Tissue–Based Kinetic Evaluation of 18F-AV-1451 for Tau Imaging , 2017, The Journal of Nuclear Medicine.
[6] Luca Passamonti,et al. 18F-AV-1451 positron emission tomography in Alzheimer’s disease and progressive supranuclear palsy , 2017, Brain : a journal of neurology.
[7] C. Rowe,et al. Tau imaging with [18F]THK‐5351 in progressive supranuclear palsy , 2017, European journal of neurology.
[8] Keith A. Johnson,et al. Pathological correlations of [F‐18]‐AV‐1451 imaging in non‐alzheimer tauopathies , 2017, Annals of neurology.
[9] M. Schain,et al. Increased basal ganglia binding of 18 F‐AV‐1451 in patients with progressive supranuclear palsy , 2016, Movement disorders : official journal of the Movement Disorder Society.
[10] C. Rowe,et al. Aβ-amyloid and Tau Imaging in Dementia. , 2017, Seminars in nuclear medicine.
[11] O. Hansson,et al. Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy , 2016, Acta Neuropathologica.
[12] J. Trojanowski,et al. Multimodal evaluation demonstrates in vivo 18F-AV-1451 uptake in autopsy-confirmed corticobasal degeneration , 2016, Acta Neuropathologica.
[13] Nick C Fox,et al. Characterization of tau positron emission tomography tracer [18F]AV-1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias , 2016, Alzheimer's & Dementia.
[14] C. Jack,et al. [18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration , 2016, Acta Neuropathologica.
[15] Kazuhiko Yanai,et al. Advances in the development of tau PET radiotracers and their clinical applications , 2016, Ageing Research Reviews.
[16] D. Brooks,et al. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET. , 2016, Brain : a journal of neurology.
[17] Clifford R. Jack,et al. An autoradiographic evaluation of AV-1451 Tau PET in dementia , 2016, Acta Neuropathologica Communications.
[18] Daniel R. Schonhaut,et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. , 2016, Brain : a journal of neurology.
[19] Daniel R. Schonhaut,et al. PET Imaging of Tau Deposition in the Aging Human Brain , 2016, Neuron.
[20] Jorge Sepulcre,et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease , 2016, Annals of neurology.
[21] Keith A. Johnson,et al. Validating novel tau positron emission tomography tracer [F‐18]‐AV‐1451 (T807) on postmortem brain tissue , 2015, Annals of neurology.
[22] Ming-Rong Zhang,et al. PET Quantification of Tau Pathology in Human Brain with 11C-PBB3 , 2015, The Journal of Nuclear Medicine.
[23] Charles DeCarli,et al. Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. , 2015, Brain : a journal of neurology.
[24] Lin Xie,et al. Radiosynthesis, Photoisomerization, Biodistribution, and Metabolite Analysis of 11C-PBB3 as a Clinically Useful PET Probe for Imaging of Tau Pathology , 2014, The Journal of Nuclear Medicine.
[25] M. Murray,et al. Differential clinicopathologic and genetic features of late-onset amnestic dementias , 2014, Acta Neuropathologica.
[26] J. Trojanowski,et al. Imaging of Tau Pathology in a Tauopathy Mouse Model and in Alzheimer Patients Compared to Normal Controls , 2013, Neuron.
[27] Robert V Farese,et al. Frontotemporal degeneration, the next therapeutic frontier: Molecules and animal models for frontotemporal degeneration drug development , 2013, Alzheimer's & Dementia.
[28] Mark Hallett,et al. Criteria for the diagnosis of corticobasal degeneration , 2013, Neurology.
[29] R. Barker,et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines , 2012, Movement disorders : official journal of the Movement Disorder Society.
[30] J. Schneider,et al. National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease , 2012, Alzheimer's & Dementia.
[31] J. Trojanowski,et al. A harmonized classification system for FTLD-TDP pathology , 2011, Acta Neuropathologica.
[32] R. Coleman,et al. Use of florbetapir-PET for imaging beta-amyloid pathology. , 2011, JAMA.
[33] D. Dickson,et al. Neuropathology of variants of progressive supranuclear palsy. , 2010, Current opinion in neurology.
[34] Jörn Diedrichsen,et al. A probabilistic MR atlas of the human cerebellum , 2009, NeuroImage.
[35] David R Williams,et al. Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges , 2009, The Lancet Neurology.
[36] Y. Agid,et al. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: The NNIPPS Study , 2008, Brain : a journal of neurology.
[37] D. Dickson. Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration , 1999, Journal of Neurology.
[38] L. Golbe,et al. A clinical rating scale for progressive supranuclear palsy. , 2007, Brain : a journal of neurology.
[39] A. Lees,et al. Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome. , 2007, Brain : a journal of neurology.
[40] Dennis W Dickson,et al. Progressive Supranuclear Palsy: Pathology and Genetics , 2007, Brain pathology.
[41] P. Lantos,et al. Office of Rare Diseases Neuropathologic Criteria for Corticobasal Degeneration , 2002, Journal of neuropathology and experimental neurology.
[42] J L Lancaster,et al. Automated Talairach Atlas labels for functional brain mapping , 2000, Human brain mapping.
[43] A. Evans,et al. Correction for partial volume effects in PET: principle and validation. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[44] I Litvan,et al. Preliminary NINDS neuropathologic criteria for Steele‐Richardson‐Olszewski syndrome (progressive supranuclear palsy) , 1994, Neurology.
[45] W. Gibb,et al. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. , 1988, Journal of neurology, neurosurgery, and psychiatry.